A higher WBC count is a predictor of hospitalization for HF, all-cause death and AMI but not for stroke in patients with concurrent Type 2 diabetes mellitus and established CAD (ESC Heart Failure)
Diabetes News
Category: Cardiovascular
A cross sectional study to compare cardiac structure and diastolic function in adolescents and young adults with youth-onset type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Study
LV structure and diastolic function is worse in individuals with T2D compared to T1D (Cardiovascular Diabetology)
The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
The cumulative evidence from the recent cardiovascular outcome trials suggests that the effects of GLP-1R activation have a beneficial effect on blood pressure and cardiovascular diseases. However, a robust meta-analysis is needed to compare the controversial results of the different papers in the current literature (Journal of Diabetes Research)
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
Our data demonstrated that initiation of empagliflozin treatment substantially reduced estimated fluid volume parameters in patients with type 2 diabetes and CVD, and that this effect was maintained for 24 weeks. Given the early beneficial effect of empagliflozin on cardiovascular outcomes seen in similar patient populations, our findings provide an important insight into the key mechanisms underlying the clinical benefit of the drug (Cardiovascular Diabetology)
Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
Prescribing patterns of SGLT-2is for glucose lowering in T2DM in primary care generally concur with licenced indications according to recommended renal thresholds. A small percentage of people with heart failure were prescribed SGLT-2is for T2DM. An updated analysis is merited should UK National Institute for Health Care and Excellence prescribing guidelines for T2DM be revised to incorporate new data on the benefits for those with reduced renal function or with heart failure (Cardiovascular Diabetology)
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
Insulin-treated patients with T2D, low HDL cholesterol, and ACS are at high risk for recurrent MACE despite the use of evidence-based, contemporary therapies (Cardiovascular Diabetology)
Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-Analysis with over 500,000 Patient-Years
The risk of HHF is reduced by SGLT2i as monotherapy or in combination with DPP4i and increased by TZD as monotherapy or in combination. Glucose-lowering provides an additive effect of reducing HHF (Journal of Clinical Endocrinology & Metabolism)
Estimated insulin sensitivity, cardiovascular risk and hepatic steatosis after 12 years from the onset of T1D
Adiposity, glucose and lipid control over the follow-up are likely to influence both. Enhanced adiposity seems paramount for the onset of hepatic steatosis in T1D patients alike in healthy youths (Diabetes/Metabolism Research and Reviews)
Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes
Our finding suggests that SAF could be useful in selecting T2D patients in whom the screening for CAD by means of CACs assessment would be more cost-effective (Acta Diabetologica)
Prediabetes and risk of heart failure: the link grows stronger
This study provides important evidence that the risk of heart failure is increased in people with a fasting plasma glucose concentration as low as 100 mg/dL, supporting the definition of prediabetes according to the American Diabetes Association guideline (Cardiovascular Diabetology)
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
With appropriate prescription and titration, pioglitazone remains a useful tool in the arsenal of the clinical diabetologist (Cardiovascular Diabetology)
Lower Risk of Hospitalisation for Heart Failure, Kidney Disease and Death with Sodium Glucose Co‐Transporter‐2 Compared to Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Regardless of Prior Cardiovascular or Kidney Disease
SGLT2i were associated with reduced risk of all–cause mortality and hospitalisation for HF and CKD compared with DPP4–i, highlighting the need to introduce SGLT2i early in the management of T2D patients (Diabetes, Obesity and Metabolism)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
SGLT2i reduced the risk of cardiac arrhythmias. Our study provides further evidence for recommending the use of SGLT2i in patients with DM, CKD, and HF (Cardiovascular Diabetology)
Significant abnormal glycemic variability increased the risk for arrhythmias in elderly type 2 diabetic patients
The study demonstrated the elderly patients had greater glycemic variability and were more prone to arrhythmias. Therefore, active control of blood glucose fluctuation in elderly patients will help to reduce the risk of severe arrhythmia (BMC Endocrine Disorders)
Diabetes management during cardiac surgery in the UK: A survey
The study demonstrates there is only limited peri‐operative management of diabetes in people undergoing cardiac surgery in the UK. There is an opportunity for greater involvement of the diabetes specialist team both before and during admission for surgery to improve outcomes (Diabetic Medicine)
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
In this review, we focus mainly on the cardiovascular benefits of SGLT2i, the underlying mechanisms, and prospects for clinical application (Cardiovascular Diabetology)
Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality
In this study, a diet with a high glycemic index was associated with an increased risk of cardiovascular disease and death (NEJM)
Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: a tripartite comparison
Regulatory authorities using identical trial data made substantially different decisions regarding both safety and efficacy of hypoglycemic drugs. The differences in initial indication wording between Japan and the other authorities suggest that trial data and T2D are interpreted differently in these regions (British Journal of Clinical Pharmacology)
Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes
Compared with Whites, Asians may derive greater CV death/HHF benefit from SGLT2is in patients with HFrEF, and MACE benefit from GLP-1RAs in patients with type 2 diabetes (Diabetes Care)
Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study
A large proportion of subjects with T2D is at high or very high risk. Glucose-lowering drug therapies seem not to be adequately used with respect to their potential advantages in terms of cardiovascular risk reduction (Cardiovascular Diabetology)
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 16
- Next Page »
Glycosmedia is also available as an App: